Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CD53
REST API REST API
Homo sapiens
CD53 is differentially expressed in 260 experiments: 122 organism parts: bone marrow, tonsil, ... (120 more);, 266 disease states: normal, glioblastoma, ... (264 more);, 101 cell types 373 cell lines 20 compound treatments and 65 other conditions.
Synonyms TSPAN25, MOX44
Orthologs Cd53 (Rattus norvegicus)   CD53_BOVIN (Bos taurus)   Cd53 (Mus musculus)   CD53 (Danio rerio)   Tsp5D (Drosophila melanogaster)   cd53 (Xenopus laevis)   CD53 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, membrane, integral to membrane, cell surface, signal transduction
InterPro Term Tetraspanin, Tetraspanin_subgr
UniProt Accession B4DQB5, P19397
Search EB-eye ENSG00000143119
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-7224, E-MEXP-433, E-GEOD-7540, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-MTAB-62, E-MEXP-1269, ... (28 experiments)

Factor Value U/D Experiments
Jurkat
3
E-GEOD-1880, E-MEXP-2197, E-MTAB-62
MCF-7
2
E-GEOD-5823, E-GEOD-20081
MOLT4
2
E-MTAB-37, E-MTAB-62
SR
2
E-MTAB-37, E-MTAB-62
HL-60
1
2
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MDA-MB-231
1
2
E-GEOD-5823, E-TABM-420, E-MTAB-62
367 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-MEXP-120, E-MEXP-66, E-GEOD-13909, ... (46 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3920, E-GEOD-3204
testis - germ cell
2
E-AFMX-5, E-TABM-145
whole blood
2
E-GEOD-3026, E-MTAB-25
CD34+ cell
1
E-MEXP-583
type I helper T cell
1
E-GEOD-3982
CD3- CD56bright CD62L+ NK cell
1
E-GEOD-21774
95 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-TABM-15, ... (67 experiments)

Factor Value U/D Experiments
glioblastoma
5
E-MTAB-37, E-GEOD-4290, E-MTAB-62, E-MEXP-567, E-GEOD-4412 ... (5 experiments)
chronic myelogenous leukemia
3
E-MTAB-62, E-MTAB-37, E-GEOD-5550
gastric carcinoma
3
E-MTAB-37, E-GEOD-15460, E-GEOD-2685
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
prostate carcinoma
1
3
E-MTAB-62, E-MEXP-2034, E-MTAB-37, E-GEOD-96
astrocytoma
2
E-GEOD-4290, E-MTAB-62
260 more value(s).


Compound treatment

studied in E-GEOD-6907, E-TABM-782, E-GEOD-3720, E-TABM-868, E-GEOD-15811, ... (15 experiments)

Factor Value U/D Experiments
none
1
6
E-TABM-782, E-GEOD-2803, E-MEXP-1958, E-TABM-868, E-GEOD-412, ... (7 experiments)
lipopolysaccharide
1
2
E-MEXP-1958, E-TABM-868, E-GEOD-3720
vanadium pentoxide
1
E-GEOD-5339
Cxcl12
1
1
E-GEOD-7307
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
N-nitrosodimethylamine
1
E-GEOD-6907
14 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-22148, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-17385

Genotype
studied in E-TABM-763, E-GEOD-2466, E-GEOD-17476, E-TABM-868

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-1446, E-GEOD-22278, E-GEOD-4425, E-MEXP-1103, ... (6 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-1657, E-GEOD-1460

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Processing time: 0.488 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM